Sprouts Farmers Market closes $600 million revolving credit facility
AstraZeneca PLC (LSE/STO/Nasdaq:LON:AZN) has released an update on its total voting rights as of May 31, 2025, according to a recent SEC filing. The company’s issued share capital with voting rights comprises 1,550,657,962 ordinary shares, each with a nominal value of $0.25. Notably, no shares are held in treasury, bringing the total number of voting rights to 1,550,657,962.
This figure is crucial for shareholders as it serves as the denominator for calculating their required notifications of any interest changes in AstraZeneca (NASDAQ:AZN) under the UK Financial Conduct Authority’s Disclosure and Transparency Rules.
AstraZeneca, headquartered in Cambridge, UK, is a global biopharmaceutical company involved in the discovery, development, and commercialization of prescription medicines. The company focuses on areas such as Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
This information is based on a press release statement filed with the SEC, reflecting AstraZeneca’s commitment to transparency and regulatory compliance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.